PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
0.15%
Cash & equivalents growing 0.15% while TRVN's declined -13.53%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
0.15%
Below half of TRVN's -13.53%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.11%
Below half of TRVN's -20.10%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.73%
≥ 1.5x TRVN's -2.84%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.07%
Below half of TRVN's 1.93%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
0.03%
Below half of TRVN's -18.32%. Michael Burry sees a potential red flag for stagnation or capital shortage.
10.13%
Less than half of TRVN's 25.06%. David Dodd sees a more disciplined AP approach or lower volume.
-6.71%
Less than half of TRVN's 2.94%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-10.13%
Below half of TRVN's -100.00%. Michael Burry suspects a big gap in pre-sales traction.
6.71%
Less than half of TRVN's -109.33%. David Dodd sees fewer expansions in other current obligations.
8.18%
Less than half of TRVN's -50.47%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-95.12%
Above 1.5x TRVN's -3.02%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
6.04%
Less than half of TRVN's -35.77%. David Dodd sees far fewer liability expansions relative to competitor.
4.76%
Higher Common Stock (Book Value) Growth compared to TRVN's zero value, indicating worse performance.
-2.66%
Similar yoy to TRVN's -2.95%. Walter Schloss sees parallel earnings retention vs. competitor.
100.00%
Less than half of TRVN's -14073748835432.80%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-0.27%
Below half TRVN's -14.13%. Michael Burry sees potential underperformance in building shareholder capital.
0.03%
Below half TRVN's -18.32%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-20.42%
Above 1.5x TRVN's -2.41%. Michael Burry sees a major jump. Investigate leverage rationale.
-0.28%
Less than half of TRVN's 14.52%. David Dodd sees better deleveraging or stronger cash buildup than competitor.